TAKEDA PHARMACEUTICAL CO LTD
No SEC Form 4 filings for $TAK in the last 30 days.
Takeda (TAK) reported Q1 2026 revenue of JPY 1.22 trillion, up 10.2% on an actual FX basis but down 0.5% at constant rates, citing Vyvanse generic erosion offset by core brands. Core operating profit was JPY 358.9 billion and core EPS JPY 154. FY2026 guidance: revenue JPY 4.64 trillion, core op profit JPY 1.16 trillion, adjusted FCF JPY 650-750B. Orzeyful China approved; U.S./Japan expected in Q2 2026.
Biotech roundup reports multiple FDA and EU approvals: Replimune’s TUDRIQEV with Bristol Myers Squibb’s nivolumab for advanced melanoma, Takeda’s ORZEYFUL for narcolepsy type 1, Moderna’s mFLUSIVA flu vaccine for adults 50+, Sanofi’s MenQuadfi expanded EU use, and Novartis’ Pluvicto combo for PSMA+ mHSPC. It also covers Lisata layoffs, Emergent restructuring and Q2 results, and deals including Tarsus-Alkeus and Evotec-Odyssey.
Takeda said the FDA approved Orzeyful (oveporexton), its first-in-class orexin receptor 2 agonist for narcolepsy type 1 in US adults. The company forecasts peak annual sales of $2bn to $3bn and plans a US launch in November, pending DEA scheduling. Approval follows two pivotal trials showing improved wakefulness and reduced cataplexy and other symptoms.
Over the past 7 days, alphai's AI scored 10 news stories mentioning TAK (TAKEDA PHARMACEUTICAL CO LTD). Coverage has skewed bullish: 9 bullish, 1 neutral, and 0 bearish.
Recent TAK coverage spans regulation, financial news and earnings.
Guidance and pipeline milestones (Orzeyful China approval, rusfertide commercialization setup, zasocitinib Phase III efficacy) shift near-term expectations for launches and cash generation.
First-in-class approval for a root-cause target can be a significant commercial and sentiment catalyst.
FDA approval of a first-in-class narcolepsy type 1 therapy is a material commercialization catalyst for Takeda, with near-term execution risk around scheduling and further label expansion.
FDA approval is a near-term positive catalyst, but commercial timing hinges on DEA scheduling and specialty-pharmacy rollout.
Approval creates a near-term commercialization and revenue catalyst, while also validating the orexin-agonist class after prior liver-toxicity issues.
alphai scores every news story that mentions TAK with an AI model for sentiment and relevance, and aggregates insider trades from TAKEDA PHARMACEUTICAL CO LTD's SEC EDGAR Form 4 filings. Figures refresh continuously.
Takeda (TAK) reported Q1 2026 revenue of JPY 1.22 trillion, up 10.2% on an actual FX basis but down 0.5% at constant rates, citing Vyvanse generic erosion offset by core brands. Core operating profit was JPY 358.9 billion and core EPS JPY 154. FY2026 guidance: revenue JPY 4.64 trillion, core op profit JPY 1.16 trillion, adjusted FCF JPY 650-750B. Orzeyful China approved; U.S./Japan expected in Q2 2026.
7 min readBiotech roundup reports multiple FDA and EU approvals: Replimune’s TUDRIQEV with Bristol Myers Squibb’s nivolumab for advanced melanoma, Takeda’s ORZEYFUL for narcolepsy type 1, Moderna’s mFLUSIVA flu vaccine for adults 50+, Sanofi’s MenQuadfi expanded EU use, and Novartis’ Pluvicto combo for PSMA+ mHSPC. It also covers Lisata layoffs, Emergent restructuring and Q2 results, and deals including Tarsus-Alkeus and Evotec-Odyssey.
7 min readTakeda said the FDA approved Orzeyful (oveporexton), its first-in-class orexin receptor 2 agonist for narcolepsy type 1 in US adults. The company forecasts peak annual sales of $2bn to $3bn and plans a US launch in November, pending DEA scheduling. Approval follows two pivotal trials showing improved wakefulness and reduced cataplexy and other symptoms.
4 min readTakeda Pharmaceutical said the FDA approved Orzeyful (oveporexton), an oral orexin receptor 2 agonist for narcolepsy type 1, based on Phase 3 FirstLight and RadiantLight trial data showing improvements across multiple symptoms. The company said it activates the orexin receptor rather than masking symptoms. DEA classification review is expected to finish in about 90 days. Takeda shares were up 1.38% to $16.95.
3 min readThe FDA approved Takeda’s twice-daily narcolepsy type 1 pill Orzeyful (orexin receptor agonist). Takeda said Phase 3 trials showed longer daytime wakefulness and reduced daytime sleepiness and muscle weakness versus existing therapies, with common side effects including insomnia and urinary urgency. The drug may expand an orexin-agonist class under development by other firms.
5 min readTakeda (TAK) said the U.S. FDA approved ORZEYFUL (oveporexton), an oral orexin receptor 2 agonist, for adults with narcolepsy type 1. The approval follows Phase 3 FirstLight and RadiantLight trials, which showed improvements in excessive daytime sleepiness and cataplexy versus placebo. Takeda expects U.S. availability after DEA scheduling within about 90 days.
4 min readTakeda (TSE:4502/NYSE:TAK) said the U.S. FDA approved ORZEYFUL (oveporexton) for adults with narcolepsy type 1. The oral orexin receptor 2 agonist approval follows Phase 3 FirstLight and RadiantLight trials showing improvements across excessive daytime sleepiness, cataplexy, and quality of life versus placebo. Takeda expects DEA scheduling within 90 days and says the approval should not significantly affect its FY ending March 31, 2027 forecast.
6 min readThe FDA approved Takeda Pharmaceuticals’ oral narcolepsy type 1 drug Orzeyful, described by the company as the first treatment targeting all symptoms by acting on orexin signaling. Approval followed two studies showing improved daytime wakefulness versus placebo. Orzeyful’s controlled-substance status is under DEA review, with a decision expected within 90 days.
4 min readChina’s National Medical Products Administration approved Takeda Pharmaceutical’s targeted orexin tablet Ao Ze Yue for type 1 narcolepsy on July 21 under priority review for patients 16+. Takeda filed in China in Jan 2026, before U.S. (Feb) and Japan (Mar), using global Phase III data. Takeda expects U.S. FDA decision in Q3 2026; global peak sales estimate $2B-$3B.
6 min readTakeda Pharmaceutical is seeking India’s support for a dengue vaccine it calls a landmark shot, according to the report. The article also notes Takeda will make a $20 million development milestone payment to Keros Therapeutics, as cited by DJ.
2 min read
